Medline Inc. research snapshot
MDLN AI stock analysis currently views Medline Inc. as a large medical-surgical products and healthcare supply-chain platform with 2026 organic-sales guidance of 8.5% to 9.5%, durable customer infrastructure, and meaningful self-manufactured product exposure. The trade-off is a short public-market history, $10.5 billion of March-quarter net debt, lower first-quarter gross margin, controlling-stockholder influence, and a valuation that leaves little room for slower growth. At the July 11, 2026 cutoff, the latest independently verified regular-session reference was $40.85 on July 9 with a $53.66 billion market capitalization. This MDLN AI stock analysis is informational research, not investment advice.
Current price
$40.85
Market cap
$53.66 billion
AI score
66 / 100
Rating
Growing healthcare distributor with leverage and valuation risk
Trend status
Neutral after a rebound from late-May weakness; confirm with a live chart
Data cutoff (updated weekly)
July 11, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Medline supplies medical-surgical products and supply-chain services across care settings, combining proprietary products with distribution, logistics, and implementation work. | High |
| Moat | Scale, regulated logistics, customer workflow integration, manufacturing, distribution density, and long healthcare-provider relationships create practical barriers, although contracts and pricing remain competitive. | Medium-high |
| Management | CEO Jim Boyle leads an established operating business, while Class B holders and designated stockholders retain meaningful influence. Investors should monitor incentives, capital allocation, and leverage reduction. | Medium |
| Financial trend | First-quarter 2026 net sales grew 10.7% to $7.352 billion, but gross margin fell to 25.0% from 27.5% and net income fell 25.8% to $239 million. | High |
| Valuation | financial_rigor.py calculates about 49.94x TTM economic-interest EPS and a 1.86% free-cash-flow yield using a $40.85 price, $0.818 TTM EPS, and $0.758 TTM FCF per share. | Medium |
| Technical trend | The July 9 close of $40.85 was above the June 26 reference near $38.79 but below late-April references around $44, which supports a neutral, unconfirmed trend view. | Low-medium |
| Risk level | Risk is elevated by net debt, margin pressure, customer and supplier concentration, reimbursement and regulatory exposure, inventory needs, litigation, and a short post-IPO record. | Medium-high |
| AI confidence | Reported sales, cash, debt, shares, and market-cap arithmetic are source-backed. Forward returns and technical levels need live data and cannot be inferred reliably from the short trading record. | High data confidence |
| Investment certainty | Medium-low certainty. Medline has a large, useful healthcare platform, but a durable investment case requires evidence that growth converts into margin, cash flow, and lower leverage. | Medium-low |
MDLN AI stock forecast
The MDLN AI stock forecast uses scenario ranges rather than a promised target. A financial_rigor.py three-scenario model using $0.818 TTM economic-interest EPS produces mechanical three-year outputs near $66.70 in a bull case, $49.50 in a base case, and $31.30 in a bear case before taxes, dividends, dilution, capital allocation, and valuation changes.
$50 to $67
More likely if 2026 organic sales meet or exceed guidance, margin pressure eases, self-manufactured products and supply-chain implementations scale, free cash flow improves, net leverage falls, and investors retain a premium multiple.
$40 to $50
More likely if organic sales grow near the 8.5% to 9.5% guidance range, adjusted EBITDA stays within the $3.5 billion to $3.6 billion outlook, debt reduction progresses, and valuation remains near current levels.
$31 to $40
More likely if procurement pricing, input costs, inventory adjustments, customer mix, reimbursement changes, integration costs, or leverage reduce earnings and the market assigns a lower multiple.
MDLN AI technical analysis
MDLN AI technical analysis uses a July 9, 2026 close of $40.85 as the latest independently verified regular-session reference at the July 11 cutoff. The short listed history and lack of independently verified current 50-day and 200-day averages mean these levels are monitoring references, not live trade signals.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $40.85 | StockAnalysis regular-session close on July 9, 2026. Confirm the live quote before acting. |
| Near support | Around $39 | This area is near the June 26 public reference of $38.79 and is a monitoring zone, not a validated support level. |
| Near resistance | Around $44 to $45 | Late-April public price references were near $44.01 to $44.68. A live chart is needed to confirm relevance. |
| 50-day moving average | Live data required | No independently verified 50-day figure was available in the static source set at the cutoff. |
| 200-day moving average | Live data required | MDLN has limited post-IPO history, so a conventional 200-day reading should be treated with caution even when available. |
| Momentum | Neutral | The move from late-June to July improved the short-term reference price, but the stock remained below late-April references. |
| Volume | Confirm on breakout | Use live average volume to test whether a move above resistance has broad participation. |
| Volatility | Elevated post-IPO risk | Earnings, secondary offerings, lock-up dynamics, debt news, guidance, and market sentiment can change the range quickly. |
| Invalidation | Sustained break below the $39 area | A persistent break below the June monitoring area, especially with weaker margin or guidance data, weakens a constructive thesis. |
MDLN AI trading strategy
The MDLN AI trading strategy is a rules-based research framework for a recently listed healthcare distributor. It is not personalized advice. Confirm current chart data, define position size and invalidation, and review earnings dates before acting.
Wait for MDLN to clear the $44 to $45 monitoring area with live moving-average confirmation and stronger-than-average volume. Pair the chart with evidence that sales growth is converting to stable margin and free cash flow.
Invalidate the setup on a sustained loss of the $39 monitoring area, a cut to organic-sales or EBITDA guidance, or a material increase in leverage.
Monitor whether MDLN holds near $39 while customer implementations, organic sales, gross margin, cash conversion, and net leverage remain consistent with management disclosures.
Do not average down solely because the share price is lower. Reassess if gross margin, working capital, customer demand, or debt reduction deteriorate.
Track organic sales, Medline Brand and Supply Chain Solutions segment performance, gross margin, adjusted EBITDA, free cash flow, total debt, cash, net leverage, secondary offerings, and management guidance.
Reduce confidence if growth relies on lower-quality volume, margin compression persists, cash conversion weakens, or controlling holders sell material blocks without offsetting business progress.
Investment research summary
Healthcare providers pay Medline for reliable medical-surgical product availability, proprietary products, inventory access, logistics, implementation support, and supply-chain execution across care settings.
The moat is operational: national distribution capacity, healthcare compliance, manufacturing, data and workflow integration, customer relationships, and the difficulty of replacing a broad, dependable supply-chain partner.
The thesis can fail if pricing pressure and input costs compress margin while debt remains high, customers or suppliers shift volume, reimbursement or regulation changes, inventory becomes inefficient, or new public-market holders demand a lower multiple.
Jim Boyle and the operating team have a long-running platform to manage, but investors should evaluate capital allocation, debt reduction, equity conversion, secondary sales, and the influence of designated stockholders alongside operating execution.
Aging populations, care outside hospitals, provider cost pressure, supply-chain resilience needs, and the push for clinical efficiency support demand. Procurement cycles, reimbursement rules, hospital budgets, and product mix can still pressure economics.
At roughly 49.94x TTM economic-interest EPS and a 1.86% calculated free-cash-flow yield, the price assumes further growth and improved cash conversion. Margin of safety improves only if operational progress outpaces the valuation and balance-sheet risks.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| MDLN price | $40.85 at the July 9, 2026 close | StockAnalysis market-cap page | July 11, 2026 |
| Market capitalization | $53.66 billion, price times 1.313B economic-interest shares | StockAnalysis, checked with financial_rigor.py | July 11, 2026 |
| Economic-interest share count | 1.314 billion diluted shares assuming Class B exchange | Medline first-quarter 2026 results | July 11, 2026 |
| FY2025 net sales | $28.432 billion, up 11.5% | Medline 2025 10-K and StockAnalysis, cross-validated | July 11, 2026 |
| FY2025 net income | $1.159 billion | Medline 2025 10-K and Macrotrends, cross-validated | July 11, 2026 |
| March 2026 quarter net sales | $7.352 billion, up 10.7% | Medline first-quarter 2026 results | July 11, 2026 |
| March 2026 gross margin | 25.0%, down from 27.5% | Medline first-quarter 2026 results | July 11, 2026 |
| Cash and debt | $2.236 billion cash and $12.755 billion total debt | Medline Q1 release and StockAnalysis, cash cross-validated | July 11, 2026 |
| 2026 management outlook | 8.5% to 9.5% organic sales growth and $3.5 billion to $3.6 billion adjusted EBITDA | Medline first-quarter 2026 results | July 11, 2026 |
This MDLN AI stock analysis page is an informational tool only and is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available public data as of July 11, 2026 and can be wrong if fundamentals, valuation, technical trends, or market conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
